OR WAIT null SECS
November 02, 2021
Takeda’s acquisition of GammaDelta Therapeutics expands their immuno-oncology and innate immune cell therapy portfolio.
Aceragen’s acquisition of Arrevus adds key treatment candidates to its rare disease pipeline.
Following the acquisition, Avantor will have access to Masterflex’s various bioproduction operations.
October 29, 2021
The research collaboration between Sartorius and Matica Biotechnology will aim to optimize PAT technologies, automation software, and single-use platforms for large-scale viral vector production.
The $691 million deal will see Vertex use Mammoth’s systems to discover and develop in-vivo gene-editing therapies.
Ajinomoto and its subsidiary company, Ajinomoto Genexine, have partnered with Insilico Biotechnology to accelerate and improve process development and production of biologics using digital twin technology.
Merck’s agreement with the Medicines Patent Pool (MPP) aims to facilitate affordable global access for molnupiravir.
October 22, 2021
Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.
Ferrer and Treeway, have entered into a license agreement for the development and commercialization of an oral formulation of edaravone (TW001/FNP122).
October 21, 2021
The $19 million contract will expand production capacity of Aptar’s Activ-Film technology, which is used in COVID-19 testing kits.